These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 7707100)

  • 21. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
    Hernández Borrero LJ; El-Deiry WS
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 in cancer: a paradigm for modern management of cancer.
    Steele RJ; Lane DP
    Surgeon; 2005 Jun; 3(3):197-205. PubMed ID: 16076005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor suppressor gene p53].
    Tokino T
    Nihon Rinsho; 1996 Apr; 54(4):960-4. PubMed ID: 8920657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between the tumor suppressor p53 and immune responses.
    Menendez D; Shatz M; Resnick MA
    Curr Opin Oncol; 2013 Jan; 25(1):85-92. PubMed ID: 23150340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in p53 research: an interdisciplinary perspective.
    Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
    Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53: balancing tumour suppression and implications for the clinic.
    Buganim Y; Rotter V
    Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological and clinical importance of the p53 tumor suppressor gene.
    Velculescu VE; El-Deiry WS
    Clin Chem; 1996 Jun; 42(6 Pt 1):858-68. PubMed ID: 8665676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 family members in cancer diagnosis and treatment.
    Machado-Silva A; Perrier S; Bourdon JC
    Semin Cancer Biol; 2010 Feb; 20(1):57-62. PubMed ID: 20206267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
    Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
    Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.
    Peller S
    Semin Cancer Biol; 1998; 8(5):379-87. PubMed ID: 10101803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of the p53 gene.
    Sidransky D; Hollstein M
    Annu Rev Med; 1996; 47():285-301. PubMed ID: 8712782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 and apoptosis.
    Bellamy CO
    Br Med Bull; 1997; 53(3):522-38. PubMed ID: 9374035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA damage, oncogenesis and the p53 tumour-suppressor gene.
    Lee JM; Abrahamson JL; Bernstein A
    Mutat Res; 1994 Jun; 307(2):573-81. PubMed ID: 7514730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The p53 gene and protein in bronchial carcinogenesis:from biological to clinical aspects].
    Zalcman G; Trédaniel J; Lechapt E; Lubin R; Soussi T; Hirsch A
    Rev Mal Respir; 1994; 11(5):455-72. PubMed ID: 7816989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the cell cycle regulatory genes p16INK4A and p21WAF1 and the metastasis-inducing gene S100A4 are infrequent and unrelated to p53 tumour suppressor gene status and data on survival in oropharyngeal squamous cell carcinomas.
    Ibrahim SO; Lillehaug JR; Vasstrand EN
    Anticancer Res; 2003; 23(6C):4593-600. PubMed ID: 14981901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borealin is repressed in response to p53/Rb signaling.
    Date DA; Jacob CJ; Bekier ME; Stiff AC; Jackson MW; Taylor WR
    Cell Biol Int; 2007 Dec; 31(12):1470-81. PubMed ID: 17716930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.